ANI Pharmaceuticals offers to acquire Egetis Therapeutics for SEK 5.6 billion
ANIP•ANIP•ANIP•ANIP•ANI Pharmaceuticals offered to acquire Egetis Therapeutics for approximately SEK 5.6 billion ($560 million), or SEK 11.25 per share, a 27% premium to Egetis’ 60-day volume-weighted average share price. Egetis’ board unanimously supports the offer, which is backed by shareholders controlling approximately 42%.
ANI Pharmaceuticals offered to acquire Egetis Therapeutics for approximately SEK 5.6 billion ($560 million). The SEK 11.25-per-share offer represents a 27% premium to Egetis’ 60-day volume-weighted average share price and implies an enterprise value of approximately $434 million, adjusted for estimated net proceeds from Egetis’ priority review voucher sale.
Egetis’ MCT8-deficiency treatment EMCITATE has estimated peak sales potential exceeding $300 million in its approved indication and patent protection into 2045. Egetis’ board unanimously supports the offer, which is backed by shareholders controlling approximately 42%; financing combines cash with new JPMorgan Chase debt.
